One catalyst not being paid enough attention to is the company’s July 31 investor day, says analyst Bob Hopkins. New projects and opportunities coming in the relatively near-term will be highlighted, he says, and investors should leave the meeting more convinced that double-digit revenue growth is sustainable.
He upgrades Cardiovascular Systems (NASDAQ:CSII) to Buy from Underperform and lifts his price target to $40 from $30. That would be about 33% upside from yesterday’s close.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.